These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25070434)

  • 41. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
    Webendörfer S; Riemann JF
    Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective cohort study of compliance with faecal immunochemical tests for colorectal cancer screening in Hong Kong.
    Wong MC; Ching JY; Lam TY; Luk AK; Hirai HW; Griffiths SM; Chan FK; Sung JJ
    Prev Med; 2013 Sep; 57(3):227-31. PubMed ID: 23732241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.
    Lo SH; Halloran S; Snowball J; Seaman H; Wardle J; von Wagner C
    Gut; 2015 Feb; 64(2):282-91. PubMed ID: 24812001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Results of the Czech National Colorectal Cancer screening programme -  faecal occult blood tests].
    Seifert B; Májek O; Zavoral M; Král N; Suchánek S; Ngo O; Dušek L
    Klin Onkol; 2014; 27 Suppl 2():87-97. PubMed ID: 25494893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is the type of test used for mass colorectal cancer screening a determinant of compliance? A cluster-randomized controlled trial comparing fecal occult blood testing with flexible sigmoidoscopy.
    Federici A; Marinacci C; Mangia M; Borgia P; Giorgi Rossi P; Guasticchi G
    Cancer Detect Prev; 2006; 30(4):347-53. PubMed ID: 16965874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do socioeconomic factors play a role in nonadherence to follow-up colonoscopy after a positive faecal immunochemical test in the Flemish colorectal cancer screening programme?
    Hoeck S; van de Veerdonk W; De Brabander I
    Eur J Cancer Prev; 2020 Mar; 29(2):119-126. PubMed ID: 31724969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program.
    Seeff LC; Royalty J; Helsel WE; Kammerer WG; Boehm JE; Dwyer DM; Howe WR; Joseph D; Lane DS; Laughlin M; Leypoldt M; Marroulis SC; Mattingly CA; Nadel MR; Phillips-Angeles E; Rockwell TJ; Ryerson AB; Tangka FK
    Cancer; 2013 Aug; 119 Suppl 15():2820-33. PubMed ID: 23868476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct mailing of faecal occult blood tests for colorectal cancer screening: a randomized population study from Central Italy.
    Giorgi Rossi P; Grazzini G; Anti M; Baiocchi D; Barca A; Bellardini P; Brezzi S; Camilloni L; Falini P; Maccallini V; Mantellini P; Romeo D; Rubeca T; Venditti MA
    J Med Screen; 2011; 18(3):121-7. PubMed ID: 22045820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
    Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
    Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. False-positive results from colorectal cancer screening in Catalonia (Spain), 2000-2010.
    Garcia M; Milà N; Binefa G; Borràs JM; Espinàs JA; Moreno V
    J Med Screen; 2012 Jun; 19(2):77-82. PubMed ID: 22653571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Lesions detected in a colorectal cancer screening program in the Basque Country: first round (2009-2011)].
    Portillo I; Idígoras I; Ojembarrena E; Arana E; Luis Hurtado J; Basurko R; Tapia M; Luz Peña M
    Gastroenterol Hepatol; 2013 May; 36(5):301-8. PubMed ID: 23618538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Colorectal cancer screening programme by faecal occult blood test in Tuscany: first round results.
    Grazzini G; Castiglione G; Ciabattoni C; Franceschini F; Giorgi D; Gozzi S; Mantellini P; Lopane P; Perco M; Rubeca T; Salvadori P; Visioli CB; Zappa M
    Eur J Cancer Prev; 2004 Feb; 13(1):19-26. PubMed ID: 15075784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
    Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
    Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telephone assessment increases uptake of colonoscopy in a FOBT colorectal cancer-screening programme.
    Rodger J; Steele RJ
    J Med Screen; 2008; 15(2):105-7. PubMed ID: 18573779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.